Bionor Immuno AS
- Country
- 🇳🇴Norway
- Ownership
- Subsidiary
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.bionorpharma.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
- Conditions
- HIV I Infection
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Bionor Immuno AS
- Target Recruit Count
- 26
- Registration Number
- NCT02092116
- Locations
- 🇩🇰
Aarhus University Hospital, Skejby Sygehus, Aarhus N, Denmark
Re-boosting of HIV-1 Infected Subjects With Vacc-4x
- Conditions
- HIV-1 Infection
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Bionor Immuno AS
- Target Recruit Count
- 33
- Registration Number
- NCT01712256
- Locations
- 🇺🇸
UCLA CARE Center, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇩🇪EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125, Berlin, Germany
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Bionor Immuno AS
- Target Recruit Count
- 36
- Registration Number
- NCT01704781
- Locations
- 🇩🇪
EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125, Berlin, Germany
🇩🇪Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1, Berlin, Germany
🇩🇪University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Vacc-C5/GM-CSFDrug: Vacc-C5/Alhydrogel
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Bionor Immuno AS
- Target Recruit Count
- 36
- Registration Number
- NCT01627678
- Locations
- 🇳🇴
Oslo University Hospital, Ullevål, Oslo, Norway
Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Bionor Immuno AS
- Target Recruit Count
- 137
- Registration Number
- NCT00659789
- Locations
- 🇺🇸
UCLA CARE Center, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States